Remove 2018 Remove Engineering Remove Licensing
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. Trends Immunol 39(6):446-459 (2018).

Therapies 105
article thumbnail

Sana Bio’s $150 Million IPO Expected to Provide Market Valuation of $10 Billion

The Pharma Data

Based in Seattle, Washington, Sana focuses on in vivo and ex vivo cell engineering platforms to develop therapies for cancer, diabetes, cardiovascular disease, CNS disorders, and genetic diseases. When the company launched an IPO in late 2018, its valuation was $7 billion, which at the time was a record biotech IPO.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA Action Alert: MacroGenics and Amgen

The Pharma Data

MacroGenics , based in Rockville, Maryland, has a target action date of December 18 for its Biologics License Application (BLA) for margetuximab in combination with chemotherapy for patients with metastatic HER2+ breast cancer. Margetuximab is an investigational, Fc-engineered, monoclonal antibody targeting HER2.

FDA 52
article thumbnail

Crescendo Biologics Expands its Ongoing Collaboration with Takeda

The Pharma Data

Under its ongoing collaboration and license agreement, Crescendo’s proprietary transgenic platform and engineering expertise is being used to build Humabody ® -based therapeutics against certain targets selected by Takeda. This is the sixth technical milestone achieved by Crescendo in its collaboration with Takeda.

article thumbnail

Where's the Synthetic Blood?

Codon

5 An added benefit of PSCs is that they are amenable to genetic modifications, making it possible to engineer blood cells with specific properties. Cultured red blood cells can also be genetically engineered to act as synthetic sensors that detect circulating molecules inside the body. Science Robotics (2018).

article thumbnail

Hemogenyx Pharmaceuticals PLC Announces Update on CDX Antibody Development

The Pharma Data

On 14 May 2018, the Company announced a collaboration with GlobalCo to work on its CDX antibody. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.

article thumbnail

Innate Pharma 2021 Financial Calendar

The Pharma Data

Innate Pharma’s commercial-stage product, Lumoxiti, in-licensed from AstraZeneca in the US, EU and Switzerland, was approved by the FDA in September 2018. About Innate Pharma: Innate Pharma S.A. Lumoxiti is a first-in class specialty oncology product for hairy cell leukemia.